The BCL‐2 family protein inhibitor ABT‐737 as an additional tool for the treatment of EBV‐associated post‐transplant lymphoproliferative disorders

Abstract

Post-transplant lymphoproliferative disorders (PTLD) and Burkitt's lymphoma (BL) are B-cell malignancies strongly associated with Epstein-Barr virus (EBV) infection. In these lymphoproliferative disorders, EBV infection induces an increase in the expression of the anti-apoptotic protein BCL-2. Given its chemoprotective effect, BCL-2 constitutes an attractive target for new therapeutic strategies for EBV-positive B-cell malignancies. Here, we show that ABT-737, a small inhibitor of BCL-2, BCL-X(L), and BCL-w, strongly induced apoptosis in vitro in EBV-positive lymphoblastoid cell lines (which is a model for PTLD), whereas BL was less sensitive. ABT-737 reduced tumor growth and increased the overall survival of mice in a xenograft model of PTLD but had no effect on BL xenograft mice. ABT-737 combined with a low dose of cyclophosphamide, a major component of the conventional CHOP chemotherapy regimen for BL patients, reduced tumor growth during treatment but failed to improve the overall survival of BL xenograft mice. By contrast, the combination of ABT-737 and rituximab, one of the main options for the treatment of PTLD, was highly efficient and induced approximately 70% remission in PTLD xenograft mice. These results suggest that the use of agents targeting BCL-2, either alone or in combination with other conventional drugs, represents a novel promising approach for post-transplant EBV-positive B lymphoproliferative disorders.

Copper induces oxidative stress and apoptosis of hippocampal neuron via pCREB/BDNF/ and Nrf2/HO‐1/NQO1 pathway

“…Accumulating evidence has shown that deceased ratio of antiapoptotic member Bcl-2 and pro-apoptotic Bax contribute to mitochondrial dysfunction and apoptosis (Robert et al, 2020). This is because that increase in Bcl-2 /Bax ratio prohibits Bax translocation to the mitochondria and then prevents cells from apoptotic (Yu et al, 2003).…”

Ganoderma lucidum Spore Polysaccharide Inhibits the Growth of Hepatocellular Carcinoma Cells by Altering Macrophage Polarity and Induction of Apoptosis

“…The BCL-2 family members are located on the mitochondria and can control its permeability, the release of cytochrome C, the activation of “priming” CASP-9, and the subsequent activation of “executive” CASP-3. Endogenous apoptosis can be inhibited through prosurvival signaling pathways such as PI3K/AKT and MAPK [ 31 , 32 ]. The PI3K/AKT pathway is an intracellular signaling pathway with phosphatidylinositol kinase and serine/threonine kinase activity.…”

“…PTEN has a negative regulatory effect on the PI3K/AKT pathway [ 34 ]. Activated AKT can phosphorylate and inhibit Bad, BAX, CASP-9, GSK-3, and FOXO1 [ 32 ]. Western blot and RT-qPCR results showed that GLSP downregulated the expression of PI3K and p-AKT genes and proteins in H22 cells.…”

Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review

“…Although their use in PTLD has been very limited, there seems to be a strong in vitro rationale in PTLD as well. 65,66 In addition, some of these molecules, including the Bruton tyrosine kinase inhibitor ibrutinib, may also be effective in graft rejection.…”